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Abstract
Background: Knee osteoarthritis (KOA) is a major public health issue causing chronic disability as well as a burden
on healthcare resources. In China, a herbal drug tablet has been used as an effective and conventional therapy to
alleviate clinical symptoms caused by KOA. However, evidence gathered from systematic reviews or randomized
controlled trials that validated herbal drugs for the management of osteoarthritic pain is weak. The purpose of this
study is to explore the efficacy and safety of the Shaoyao Shujin tablet for the management of KOA in a short-term
study.
Methods/Design: This trial is a multicenter randomized, double-blind, placebo-controlled study. A total of 276
patients will be randomized into 3 groups: (1) the high-dose Shaoyao Shujin tablet group (HD group), (2) the
low-dose Shaoyao Shujin tablet group (LD group), and (3) the placebo tablet group (control group). In the
three groups, four tablets will be administered three times per day for 6 weeks. Follow-up will be at regular
intervals during a 10-week period with the Western Ontario and McMaster Universities Index (WOMAC) score,
visual analog scale (VAS) score, and rescue medication use assessed as outcome measures.
Discussion: This study will provide clinical evidence on the efficacy and safety of the Shaoyao Shujin tablet in
treating KOA.
Trial registration: Chinese Cochrane Center ChiCTR-IPR-15006194, registered 4 April 2015.
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Background
Knee osteoarthritis (KOA) is a prevalent disease causing
disability in the aging population. The risk of KOA dis-
ability, characterized as chronic pain and functional limi-
tation, is as great as that attributable to cardiovascular
disease and greater than that due to any other medical
condition in older persons [1]. In the US, estimated aver-
age discounted (3 % per year) lifetime costs for persons
diagnosed with KOA were US$140,300, and direct med-
ical costs were US$129,600, with US$12,400 (10 %) at-
tributable to KOA over 28 years [2]. Determining
effective means of treating KOA has become an import-
ant subject of study, particularly because currently there
is no medical treatment to reverse or stop its progres-
sion. Pharmacological approaches include analgesics,
anti-inflammatory agents, corticosteroids given by the
intra-articular route, or hyaluronic acid, glucosamine
sulfate, and chondroitin sulfate, which are already widely
use. However, these drugs have some adverse effects
such as constipation, nausea, and excessive sedation in
older people, and their effect on cartilage with OA
changes remains controversial [3–5].
The aim of KOA treatment is to reduce pain, improve
physical function, prevent disability, and enhance short-
term quality of life. The herbal drug the Shaoyao Shujin
tablet (SST, previously called Yangxue ruanjian jiaonang)
is a multicomponent Chinese herbal supplement that
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has been proved to be an effective regimen to relieve
KOA pain in patients [6] or to delay the degeneration of
articular cartilage in KOA animal models [7, 8]. How-
ever, understanding of the mechanisms responsible for
the beneficial effects of SST is limited and its clinical ef-
fectiveness needs strong evidence for proof. Published
Chinese medical literature has documented that SST is
efficacious in treating KOA, but these interventions have
not been rigorously evaluated, and their credibility ques-
tioned, due to a lack of objective evidence [9]. Therefore,
we designed a multicenter randomized, double-blind,
placebo-controlled trial to explore the efficacy and safety




This is a multicenter randomized, double-blind, placebo-
controlled trial. General ethical approval was issued by the
Ethics Committee of Guangdong Provincial Hospital of
Chinese Medicine (No. A2015-01-2-1), and participating
center ethical approval was issued by the Clinical Trial
Ethics Committee of Huazhong University of Science and
Technology (No. FZ-1302-01), the Ethics Committee of
The First Affiliated Hospital of Anhui University of TCM
(No. 2015AH-03), the Clinical Trial Ethics Committee of
The First Affiliated Hospital of Hunan University of TCM
(No. 2015-YW-001), and the Ethics Committee of Shang-
hai Hospital of TCM (No. 2015SHL-05). Subjects will be
enrolled at these five hospitals. The trial protocol has been
registered in the Chinese Clinical Trial Registry (ChiCTR-
IPR-15006194). All study participants will sign the written
informed consent before participation. The trial is finan-
cially supported by Shanghai Fosun Pharmaceutical Devel-
opment Co., Ltd, Shanghai, China, which will participate
in the study design, but will not be involved in data collec-
tion, data management, analysis, interpretation of data or
the decision to submit the report for publication, but will
provide all test drugs.
Recruitment and consent
A target sample size of 276 KOA patients, who are regu-
larly followed up at outpatient clinics of the Department
of Orthopedic Surgery in each participating center, will
be recruited. All candidates will go through a standard-
ized interview process and receive more information
about the study and the treatments. The purpose, proce-
dures, and potential risks and benefits of the study will
also be explained thoroughly to the participants. The
more painful knee will be chosen as the study knee, and
if both knees have the same symptoms, we will choose
the right side. The participants will be able to withdraw
from the study at any time without consequence. The
trial will be executed from February 2015 to February
2016 including enrollment and follow-up (see Fig. 1).
Inclusion criteria
Participants meeting the following criteria will be
included:
 Meet the diagnostic criteria for KOA (American
College of Rheumatology criteria [10])
 Aged from 40 to 70 years old
 Symptomatic KOA with pain of at least 30 mm on a
100-mm visual analog scale (VAS)
 Grade 0–3 on the Kellgren-Lawrence grading
system
 No serious medical history
 No known drug allergies
 Willingness to give written informed consent and
willingness to participate in, and comply with, the
study
Exclusion criteria
Participants meeting one or more of the following
criteria will be excluded:
 Grade 4 on the Kellgren-Lawrence grading system
 Medication history for KOA within 1 week, such as
NSAIDs, steroids, glucosamine, chondroitin sulfate,
sodium hyaluronate, etc.
 Allergy to study drug
 Non-degenerative osteoarthritis, such as rheumatoid
arthritis, gouty arthritis, infectious arthritis, Charcot
arthritis, etc.
 Unwilling to give informed consent
Interventions
Eligible patients will be randomized into the three
groups: (1) the high-dose SST group (HD group), (2) the
low-dose SST group (LD group), and (3) the placebo tablet
group (control group). The SST will be provided by the
Shanghai Fosun Pharmaceutical (Group) Co., Ltd,
Shanghai, China (drug permit license number 2014L00464)
and weighs 0.35 g per tablet. The components of the
SST are Radix paeoniae alba, Radix Gentianae Macro-
phyllae, oyster, licorice, scorpion, and centipede. The
placebo tablet will be manufactured identical to the
SST in terms of color and odor by the same manufac-
turer. In the HD group four SSTs will be administered
three times per day for 6 weeks, while in the LD group
two SSTs and two placebo tablets, and in the control
group four placebo tablets at the same frequency and for
the same duration. Patient visits will be performed at base-
line and 2, 4, 6 and 10 weeks after treatment. Assess-
ments including the Western Ontario and McMaster
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Fig. 1 Study flow-chart
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Universities Index (WOMAC) score and the VAS score
will be recorded on the relevant knee during all visits.
As a short-term study aims to explore the efficacy and
safety of SST for the symptomatic management of KOA,
we think that 6 weeks’ treatment and 4 weeks’ follow-up
will be enough to observe whether there are differences
between the HD group, the LD group and the placebo
tablet group.
During the process, when patients experience moder-
ate pain or a VAS score over 40 mm, ibuprofen
sustained-release capsules will be administrated as res-
cue medication. Rescue medication consumption and
time will be recorded in each randomized group when
the subjects use rescue medication. The patients will not
be allowed to use other drugs aiming to treat KOA.
Outcome measures
Primary outcome measure
The primary efficacy endpoint of the study will be the
WOMAC score [11]. The WOMAC score is a widely
used proprietary set of standardized questionnaires used
by health professionals to evaluate the condition of pa-
tients with osteoarthritis of the knee and hip, including
pain, stiffness, and physical functioning of the joints.
The index measures five items for pain (score range 0 to
20), two for stiffness (score range 0 to 8), and 17 for
physical function (score range 0 to 68). It will be mea-
sured during all the assessment visits (baseline, 2-, 4-, 6-
and 10-week follow-up).
Secondary outcome measure
The secondary efficacy endpoint of the study will be
the VAS score, which is a pain score ranging from 0
mm (no pain) to 100 mm (worst pain ever experienced)
[12], measured during all the assessment visits (baseline,
2-, 4-, 6- and 10-week follow-up). The VAS score is usu-
ally a horizontal line, 100 mm in length, anchored by word
descriptors at each end. Patients mark the point of their
current pain on the line. The VAS score is then deter-
mined by measuring in millimeters from the left end of
the line to the point that the patient marked.
Safety assessments
All subjects will be questioned about adverse events dur-
ing the treatment at each visit, and all adverse events re-
ported will be analyzed, regardless of the investigators’
assessments of causality. Safety will be assessed by the
following tests on all subjects: physical examination
(temperature, respiration, heart rate, blood pressure,
height and weight), complete blood cell count, urinalysis,
stool examination, fecal occult blood test, liver function
(alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), alkaline phosphatase (ALP), serum total
bilirubin (STB), and γ-glutamyl transpeptidase (γ-GT)),
renal function (creatinine (Cr), micro-albuminuria,
serum cystatin C, and urinary N-acetyl-β-glucosamini-
dase) and an electrocardiogram (ECG) at baseline and at
2- and 6-week visits.
Randomization and blinding
Patients who meet the inclusion criteria will be randomly
assigned to one of three groups (HD group, LD group,
control group) in a ratio of 1:1:1 using a computer-
generated random allocation sequence through the strati-
fied block randomization method of SAS version 9.1.3
(SAS Institute Inc., Cary, NC, USA). Each patient will re-
ceive a unique randomized test number corresponding to
the specified drug, according to the group allocation. An
emergency envelope has been prepared for each test
number and is to be opened.
The trial will be blinded to both patients and treating
physicians. For test drug blinding, the placebo tablet will
be manufactured identical to the SST in terms of color
and odor. The drugs are administered by an independent
clinical assistant in each center who takes responsibility
for the drugs’ distribution, storage and return. Any
members who have access to the drug will not partici-
pate in case observations or efficacy evaluations. Before
the trial two different bottles will be prepared: bottle A
contains a 2-week dose of SSTs and bottle B contains a
2-week dose of placebo tablets. Bottles A and B will be
packaged with the same label for patient and assessor
blinding. For the HD group, two A bottles will be
assigned; for the LD group, one A bottle and one B
bottle will be assigned; and for the control group, two
B bottles will be assigned. During baseline, and 2-, and
4-week visits, patients will be assigned two bottles ac-
cording to their group, and 14 rescue medications.
They will then be instructed to take two tablets from
each bottle every time they take their drugs. At the
next visit, the patient should return all the rescue
medications they didn't taken.
Sample size
Calculation of sample size is based on a similar herbal
drug study assessing the short-term efficacy of two types
of Traditional Chinese herbal patches, Fufang Nanxing
Zhitong Gao and Shangshi Jietong Gao [13]. We estimate
that an absolute improvement of 10 in the WOMAC
total score is likely to be the smallest clinically relevant
difference for patients with KOA. We assume that the
standard deviation of the total WOMAC score to be
18.2 at baseline. Based on these assumptions, we will re-
quire 79 patients in each group to have at least an 80 %
power (β = 0.8) and to rule out a two-sided type I error
of 5 % (α = 0.05). The number of patients actually pro-
vides less than 80 % power, assuming a withdrawal rate
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of 15 %. Therefore, we will recruit a total of 276 patients,
92 patients in each group.
Statistical analysis
The data will be collected and analyzed according to the
intention-to-treat principle. An analysis of variance
(ANOVA) or chi-square test will be used to compare
baselines among patients. Efficacy analyses will be per-
formed for both the intent-to-treat (ITT) population and
the per-protocol (PP) population. The ITT population
will consist of all randomized subjects who have been
administered at least one treatment. In a PP analysis,
only patients who complete the entire clinical trial ac-
cording to the protocol are counted towards the final re-
sults. Primary outcome will be compared among groups;
the extent and time pattern of rescue medication use in
each randomized group will be reported: in considering
comparison of the underlying outcomes of rescue medi-
cation use, we will assume the use varies with time and,
to allow for dependence within patients, we will adopt a
multilevel regression approach with rescue as a time-
dependent covariate [14]. All statistical analyses will be
performed using SAS 9.2 software. All statistical tests
will be two-sided, and the level of significance will be set
at 0.05.
Discussion
This study will provide clinical evidence on the efficacy
and safety of SST in treating KOA. Despite considerable
research, there is no specific remedy for patients who
suffer from OA. Various complementary and alternative
medical treatments have been administered for OA in
clinical practices [15–17]. Some studies have reported
the effectiveness of herbal medicine, which is the most
popular form of complementary and alternative medical
therapy for the treatment of OA [18–21]. Insects have
also been used globally as traditional medicines for cen-
turies [22]. Several studies have shown that leeches have
a remarkable effectiveness in treating osteoarthritis pain
[23–25]. As a Traditional Chinese Medicine (TCM) for-
mula, SST, containing herbal medication and insects,
has been demonstrated to be effective at activating blood
circulation and assuaging pain in previous clinical obser-
vation. However, due to lack of objective evidence, a
well-designed randomized controlled trial is needed to
examine the efficacy and safety of SST for the symptom-
atic management of KOA.
Trial status
Recruitment will commence in February 2015, and the
trial will schedule to end in February 2016.
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